BSXNYSESurgical & Medical Instruments & ApparatusFiscal year ends December 31
BOSTON SCIENTIFIC CORP
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026
$45.05+0.66 (+1.49%)
Close on Oct 19, 2026
- Market cap
- $66.44B
- P/E (TTM)
- 18.2
- Dividend yield
- –
Share price
−$54.19 (−54.60%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
BOSTON SCIENTIFIC CORP grew revenue 13.5% to $21.00B over the twelve months to Jun 30, 2026. Operating income rose 31.9% to $4.15B, moving the operating margin from 17.0% to 19.8%. Free cash flow was $3.63B, up 4.0% from a year earlier.
Revenue
$21.00B
+13.5% vs. a year earlier
Operating income
$4.15B
+31.9% vs. a year earlier
Free cash flow
$3.63B
+4.0% vs. a year earlier
EPS, diluted
$2.47
+47.0% vs. a year earlier
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $66.44B
- P/E ratio
- 18.2
- Price to sales
- 3.16
- Price to book
- 2.67
- Dividend yield
- –
- Free cash flow yield
- 5.46%
Fundamentals
- Revenue
- $21.00B
- EPS, diluted
- $2.47
- Free cash flow
- $3.63B
- Book value per share
- $16.90
- Diluted shares
- 1.47B
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
$21.00B+13.5% YoY
Gross profit
$14.68B+16.3% YoY
Operating income
$4.15B+31.9% YoY
EPS, diluted
$2.47+47.0% YoY
Free cash flow
$3.63B+4.0% YoY
Reported periodTrailing twelve months